Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21

J Clin Oncol. 2011 Jun 1;29(16):e465-7. doi: 10.1200/JCO.2010.34.0216. Epub 2011 Mar 21.

Authors

Katsuhiro Masago¹, Masako Miura, Yoshiro Toyama, Yosuke Togashi, Michiaki Mishima

Affiliation

¹ Graduate School of Medicine, Kyoto University, Kyoto, Japan.

PMID: 21422425
DOI: 10.1200/JCO.2010.34.0216

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma, Papillary / drug therapy*
Adenocarcinoma, Papillary / genetics
Adenocarcinoma, Papillary / pathology
Aged
Antineoplastic Agents / therapeutic use*
Carcinoma, Signet Ring Cell / drug therapy
Carcinoma, Signet Ring Cell / genetics
Carcinoma, Signet Ring Cell / pathology
DNA Mutational Analysis
Epidermal Growth Factor / genetics*
Erlotinib Hydrochloride
Exons
Female
Humans
Immunohistochemistry
Mutation
Polymerase Chain Reaction
Quinazolines / therapeutic use*
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / genetics
Thyroid Neoplasms / pathology

Substances

Antineoplastic Agents
Quinazolines
Epidermal Growth Factor
Erlotinib Hydrochloride